KDR and cancer: Consequently, small molecule tyrosine kinase inhibitors that target the VEGFA/VEGFR2 pathway have been developed such as sunitinib, sorafenib, and axitinib that are now FDA-approved therapies for multiple advanced staged cancers such as metastatic colorectal cancer and metastatic non-small-cell lung cancer [7,8].